Arecor Limited has signed a research, development and commercialisation agreement with JDRF, the world's leading type 1 diabetes research charity.
Under the collaboration, Arecor and JDRF will invest equal funds to develop AT271, a liquid combination of insulin and pramlintide, which is used to replace a hormone absent in people with type 1 diabetes.
In a statement, the privately-owned biopharmaceutical company said it has been demonstrated that the combined injection of these two drugs at mealtimes helps with controlling the blood sugar level, losing weight and reducing insulin doses.
However, it noted, pramlintide is currently “underutilised” because there is no combined injectable solution containing insulin and patients need to carry out separate injections.
Arecor will use its proprietary formulation technology platform, Arestat to develop a new, co-formulation of pramlintide and insulin.
“The development of a co-formulation of pramlintide-insulin has the promise to significantly improve the quality of life for people living with diabetes by enabling more effective management of this condition,” said Arecor’s chief executive Sarah Howell.
“This collaboration reflects the investment we are making in our proprietary portfolio of diabetes products and we appreciate the support of such a prestigious organisation as JDRF.
The charity has invested £1bn into funding type 1 diabetes research globally since 1970.